Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients
Titel:
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients
Auteur:
Mato, A.R. Hill, B.T. Lamanna, N. Barr, P.M. Ujjani, C.S. Brander, D.M. Howlett, C. Skarbnik, A.P. Cheson, B.D. Zent, C.S. Pu, J.J. Kiselev, P. Foon, K. Lenhart, J. Henick Bachow, S. Winter, A.M. Cruz, A.-L. Claxton, D.F. Goy, A. Daniel, C. Isaac, K. Kennard, K.H. Timlin, C. Fanning, M. Gashonia, L. Yacur, M. Svoboda, J. Schuster, S.J. Nabhan, C.